TrumpRx and Prescription Drug Costs: A Look at Affordability and Regulation

As the Trump administration continues its focus on lowering prescription drug costs with initiatives like TrumpRx, a new KFF poll reveals a complex landscape of public opinion. Even as some Americans express optimism about the administration’s policies, a majority remain worried about affording their medications. This article examines the current state of prescription drug affordability, the role of government regulation, and the impact of TrumpRx, drawing on the latest data and analysis.

Public Concerns About Drug Costs Remain High

According to a KFF Health Tracking Poll released on March 13, 2026, 59% of U.S. Adults are worried about affording prescription drugs for themselves and their families – the highest percentage since KFF began polling on this issue in 2018. This concern is particularly acute among those with lower incomes (67% of those earning less than $40,000 annually) and individuals taking four or more prescription medications (64%).

Limited Optimism Regarding Trump Administration Policies

The poll indicates that only 41% of U.S. Adults believe the Trump administration’s policies will likely lower prescription drug costs for people like them. Partisanship significantly influences these views, with 79% of Republicans and 88% of Make America Great Again (MAGA) supporters expressing optimism, compared to just 35% of independents and 11% of Democrats.

TrumpRx: Awareness and Usage

TrumpRx, the federal government-run website launched in February 2026, aims to provide discounts on prescription drugs directly from manufacturers and pharmacies. As of the KFF poll, 35% of adults who currently take prescription medication have heard “a lot” or “some” about TrumpRx, an increase from 18% in November 2025. However, only 7% have visited the site to compare prices, rising to 16% among those who currently or have previously taken GLP-1 medications.

The TrumpRx website currently features approximately 40 medications, including treatments for obesity (Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound) and infertility (Gonal-F from EMD Serono) [1]. The discounts offered are the result of individual agreements between the Trump administration and 16 major drug companies [3].

Cost-Saving Measures and Alternative Options

Many Americans are already taking steps to reduce their prescription drug costs. Approximately 42% have used discount cards or coupons (like those offered by GoodRx or SingleCare), and 39% have compared prices online. A smaller percentage (15%) have purchased medications from online pharmacies without insurance, and 8% have purchased directly from manufacturers.

The Desire for Increased Government Regulation

Despite the launch of TrumpRx and other initiatives, there is broad bipartisan support for greater government regulation of prescription drug prices. 72% of adults believe there is not enough government regulation in this area, with at least two-thirds of Democrats, Republicans, and independents agreeing. This sentiment is even stronger among those currently taking prescription medications (77%).

Political Implications: Trust in Parties to Address Drug Costs

Looking ahead to the 2026 midterm elections, the Democratic Party currently holds a slight advantage in voters’ trust to address the cost of health care and prescription drugs. 38% of voters trust the Democratic Party more, compared to 28% who trust the Republican Party. However, 27% express no trust in either party to handle the issue.

Key Takeaways

• A majority of Americans (59%) are worried about affording prescription drugs.
• Optimism about the Trump administration’s policies to lower drug costs is limited, particularly among Democrats and independents.
• Awareness of TrumpRx is growing, but usage remains relatively low.
• There is widespread bipartisan support for increased government regulation of prescription drug prices.
• The Democratic Party currently has a slight advantage in voters’ trust to address drug costs.

The issue of prescription drug affordability remains a significant concern for Americans. While initiatives like TrumpRx aim to provide relief, the KFF poll suggests that broader systemic changes and increased government regulation may be necessary to address the underlying problem and restore public confidence.